Do dentists recommend hydroxyapatite toothpaste?

Their professional bodies have not, and the reason is specific rather than dismissive: in both the United States and the United Kingdom, the institutional endorsements attach to fluoride because that is what the regulatory categories were built around. Individual dentists split, and increasingly a few will suggest hydroxyapatite to a patient who has already refused fluoride. Those are two different questions and they get run together constantly.

What the American Dental Association actually says

The ADA’s own page on toothpastes has a key-points list, and the first bullet is this: “All toothpastes with a claim of cavity protection with the ADA Seal of Acceptance must contain fluoride.” Further down it repeats the point as a rule: “It is a requirement that for a toothpaste to be ADA-Accepted for anticaries claims, it must contain fluoride.”

Hydroxyapatite is not mentioned anywhere on that page — not approved, not rejected, not discussed. So no hydroxyapatite toothpaste carries the ADA Seal for cavity protection, and none can, on the current criteria. That is a statement about the rules, not a verdict on the ingredient.

It is also worth saying that “ADA approved” is not a thing. The ADA does not approve products; it awards a Seal of Acceptance, and products that hold it are described as ADA-Accepted. Any box that says approved is already telling you something about its own accuracy.

What the FDA rules mean in practice

In the United States, an anticaries toothpaste is an over-the-counter drug governed by a monograph — 21 CFR part 355. Section 355.10 lists the active ingredients a product may use to be covered by it, and there are exactly three: sodium fluoride, sodium monofluorophosphate and stannous fluoride. We searched the whole of part 355 for the string “hydroxyapatite”. It does not occur.

The consequence is concrete: a hydroxyapatite-only toothpaste in the US is sold as a cosmetic, not as an over-the-counter drug, and cannot legally carry an anticavity drug claim on its label. That is why the packaging talks about strengthening, remineralising and protecting enamel rather than preventing cavities. Those are carefully chosen words, and the care is a regulatory artefact rather than modesty.

None of this means the ingredient does not work. It means nobody has taken it through the process that would let it say so.

The research, and who paid for it

This is where the honest answer to “do dentists recommend it” lives, because the reason cautious dentists stay cautious is not ignorance of the trials. It is that they have read the acknowledgements.

Four human studies carry the caries case. Here is each one with its funding or conflict statement, quoted rather than characterised:

Three of the four are funded by, or written with employees of, the same company. The fourth declares no competing interests and tested that company’s product.

The reviews are written by the trialists

Systematic reviews are supposed to be the step where independent people weigh what everyone else produced. In this literature that separation largely does not exist.

The 2024 systematic review and meta-analysis in the Journal of Dentistry — the most-cited summary of the hydroxyapatite caries evidence — has six authors: Pawinska, Paszynska, Amaechi, Meyer, Enax and Limeback. All six also appear on the author list of the 18-month trial published the year before, which is among the clinical evidence the review assesses. Two of them, Meyer and Enax, are the manufacturer’s employees. The same three-author group of Limeback, Enax and Meyer wrote the 2021 caries meta-analysis and the 2023 dentin-hypersensitivity meta-analysis.

Fig. 1 draws that shape. It is a fact about the papers, disclosed in the papers, and we are stating it rather than alleging anything. Reviewing your own work is not misconduct; it is normal in small fields, and the alternative is often no review at all. But a reader told “a systematic review found hydroxyapatite effective” is entitled to know that the review and the trials share their authors.

Why it looks like this

Not conspiracy: economics. Fluoride is off-patent, cheap and universally available, so no company has a commercial reason to fund a trial proving something about it, and public funders consider the question answered. Hydroxyapatite is a differentiated ingredient in a premium product, so exactly one kind of organisation has a reason to pay for eighteen-month clinical trials in hundreds of people — the company selling it.

The result is a literature that is thin, recent and concentrated, and that would look the same whether the ingredient worked well or worked slightly. That is the actual problem: the funding pattern does not tell you the answer is wrong, it tells you the evidence cannot settle it on its own.

What the independent appraisals concluded

• A 2025 systematic review and meta-analysis in the Journal of Dentistry, with no manufacturer among its authors, retrieved 68 studies, found four eligible, and reported no significant differences between hydroxyapatite and fluoride toothpastes on new lesions or progression by DMFS or ICDAS.
• A 2026 scoping review in the European Journal of Pediatrics mapped 122 studies and concluded, verbatim, that “no fluoride-free category currently has evidence comparable to fluoride for long-term caries prevention in children” — while noting that hydroxyapatite has the most consistent evidence base among the alternatives.

Read together with the manufacturer-funded trials, the picture is consistent: hydroxyapatite probably does something, the effect is not clearly different from fluoride in the studies that exist, and the studies that exist are too few and too short to settle it.

What to ask a dentist, and what “recommended” means on a box

1. Ask what your own caries risk is This is the question that should drive the answer. Someone with no new cavities in a decade and someone with three fillings last year are not in the same decision.
2. Ask what they would use if you refuse fluoride Phrased that way, you will get the useful answer. Ethical guidance published in the ADA’s own journal supports helping patients who decline fluoride, including by discussing alternatives.
3. Treat “dentist recommended” on packaging as marketing It is not a regulated term, it carries no criteria, and it usually rests on a survey of unspecified size. The ADA Seal is a real, checkable thing; “recommended by dentists” is not.
4. Treat “clinically proven” as a prompt to ask which trial There are four. You now know all of them, and how long each ran.

When to see a dentist

• You have had a new cavity in the last two years and are thinking about dropping fluoride.
• You have white spots after braces, or chalky patches near the gum line.
• You are choosing for a child — see hydroxyapatite vs fluoride for children, where the trial evidence is thinner still.
• You have dry mouth, reflux, or take medication that reduces saliva. Risk changes the answer more than the ingredient does.

Fig. 1 is free to reuse under CC BY 4.0 — see the diagrams page.

References

1. Schlagenhauf U, Kunzelmann KH, Hannig C, et al. Impact of a non-fluoridated microcrystalline hydroxyapatite dentifrice on enamel caries progression in highly caries-susceptible orthodontic patients: a randomized, controlled 6-month trial. J Investig Clin Dent 2019;10(2):e12399. DOI · PubMed · Funding: see ledger
2. Amaechi BT, AbdulAzees PA, Alshareif DO, et al. Comparative efficacy of a hydroxyapatite and a fluoride toothpaste for prevention and remineralization of dental caries in children. BDJ Open 2019;5:18. DOI · PubMed · Funding: see ledger
3. Paszynska E, Pawinska M, Gawriolek M, et al. Impact of a toothpaste with microcrystalline hydroxyapatite on the occurrence of early childhood caries: a 1-year randomized clinical trial. Sci Rep 2021;11:2650. DOI · PubMed · Funding: see ledger
4. Paszynska E, Pawinska M, Enax J, et al. Caries-preventing effect of a hydroxyapatite-toothpaste in adults: a 18-month double-blinded randomized clinical trial. Front Public Health 2023;11:1199728. DOI · PubMed · Funding: see ledger
5. Pawinska M, Paszynska E, Amaechi BT, et al. Clinical evidence of caries prevention by hydroxyapatite: an updated systematic review and meta-analysis. J Dent 2024;151:105429. DOI · PubMed · Funding: see ledger
6. US Food and Drug Administration. 21 CFR Part 355 — Anticaries drug products for over-the-counter human use, §355.10. Official page, accessed 15 Sep 2026.
7. American Dental Association. Oral Health Topics: Toothpastes. Official page, accessed 15 Sep 2026.